The range of EB related mutations within the three main subtypes, giving rise to a variety of severities, means there will not be a single cure for EB. Within each EB type there will be need to be a combination of therapies designed to meet the particular needs of an individual patient.
“What Cure EB has done for research into EB is nothing short of amazing. What it needed was a driver and a focus, and Cure EB is pushing the accelerator to the floor.”
– Professor McGrath, Professor of Molecular Dermatology, King’s College Hospital, Guy’s and St Thomas’s Hospital
There is strong public support for medical research charities to find new treatments and cures for debilitating and life threatening conditions. This research will use a variety of different strategies to achieve this these aims.
Cultured cells grown in labs, tissue samples, computer models, skin equivalents and when appropriate, animals. Clinical trials may include volunteers
The decision to use animals is not taken lightly, but there instances when it necessary to use animal models. Typically this is where the benefits to the health of patients outweighs any harm to animals. There are strict laws governing their welfare and use both in the UK and other countries where our research is carried out. Our research adheres to the AMRC principles of refine, reduce and replace.
Damian Lewis talking to Professor John McGrath